Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Неалкогольная жировая болезнь печени и желчнокаменная болезнь: случайное или закономерное сочетание?
Неалкогольная жировая болезнь печени и желчнокаменная болезнь: случайное или закономерное сочетание?
Черкащенко Н.А., Ливзан М.А., Гаус О.В., Кролевец Т.С. Неалкогольная жировая болезнь печени и желчнокаменная болезнь: случайное или закономерное сочетание? Гастроэнтерология. Хирургия. Интенсивная терапия. Consilium Medicum. 2019; 3: 40–44. DOI: 10.26442/26583739.2019.3.190489
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Неалкогольная жировая болезнь печени (НАЖБП) и желчнокаменная болезнь (ЖКБ) широко распространены среди населения в целом. Ввиду общности факторов риска патогенетическая связь НАЖБП и ЖКБ не вызывает сомнения, при этом очевидно, что данная связь является двунаправленной. Спорным остается вопрос, что первично: метаболические нарушения на уровне гепатоцита или холестерин-ассоциированная патология желчного пузыря? В данном обзоре рассмотрены основные факторы риска развития НАЖБП и ЖКБ, также представлены сведения о вкладе холецистэктомии в формирование и прогрессирование НАЖБП.
Ключевые слова: неалкогольная жировая болезнь печени, желчнокаменная болезнь, ожирение, инсулинорезистентность, дефицит витамина D, холецистэктомия.
Key words: non-alcoholic fatty liver disease, cholelithiasis, obesity, insulin resistance, vitamin D deficiency, cholecystectomy.
Ключевые слова: неалкогольная жировая болезнь печени, желчнокаменная болезнь, ожирение, инсулинорезистентность, дефицит витамина D, холецистэктомия.
________________________________________________
Key words: non-alcoholic fatty liver disease, cholelithiasis, obesity, insulin resistance, vitamin D deficiency, cholecystectomy.
Полный текст
Список литературы
1. Ивашкин В.Т., Драпкина О.М., Маев И.В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2015; 25 (6): 31–41.
[Ivashkin V.T., Drapkina O.M., Maev I.V. et al. Rasprostranennost' nealkogol'noi zhirovoi bolezni pecheni u patsientov ambulatorno-poliklinicheskoi praktiki v Rossiiskoi Federatsii: rezul'taty issledovaniia DIREG 2. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2015; 25 (6): 31–41 (in Russian).]
2. Jaruvongvanich V, Sanguankeo A, Upala S. Signtificant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A systematic Review and Meta-Analisys. Dig Dis Sci 2016; 61 (8): 2389–96.
3. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol 2013; 19 (45): 8301–11.
4. McQuillian GM, McLean JE, Chiappa M et al. National Health and Nutrition Examination Survey Biospecimen Program: NHANES III (1988-1994) and NHANES 1999-2014. Vital Health Stat 2. 2015; 170: 1–14.
5. Fracanzani AL, Valenti L, Russello M et al. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non- Alcoholic Fatty Liver Disease. PLoS ONE 2012; 7 (7): e41183.
6. Комова А.Г., Маевская М.В., Ивашкин В.Т. Принципы эффективной диагностики диффузных заболеваний печени на амбулаторном этапе. Рос. журн. гастроэнтерологии, гепатологии и колопроктологии. 2014; 24 (5): 36–41.
[Komova A.G., Maevskaia M.V., Ivashkin V.T. Printsipy effektivnoi diagnostiki diffuznykh zabolevanii pecheni na ambulatornom etape. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2014; 24 (5): 36–41 (in Russian).]
7. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Рос. журн. гастроэнтерологии, гепатологии и колопроктологии. 2016; 26 (2): 24–42.
[Ivashkin V.T., Maevskaia M.V., Pavlov Ch.S. et al. Klinicheskie rekomendatsii po diagnostike i lecheniiu nealkogol'noi zhirovoi bolezni pecheni Rossiiskogo obshchestva po izucheniiu pecheni i Rossiiskoi gastroenterologicheskoi assotsiatsii. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2016; 26 (2): 24–42 (in Russian).]
8. EASL. Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016; 65 (1): 146–81.
9. Ливзан М.А. и др. Гормоны жировой ткани и неалкогольная жировая болезнь печени при метаболическом синдроме. Дневник казанской медицинской школы. 2014; 1 (4): 44–8.
[Livzan M.A. et al. Gormony zhirovoi tkani i nealkogol'naia zhirovaia bolezn' pecheni pri metabolicheskom sindrome. Dnevnik kazanskoi meditsinskoi shkoly. 2014; 1 (4): 44–8 (in Russian).]
10. Гаус О.В., Ахмедов В.А. Иммунологические параллели в течении метаболического синдрома, ассоциированного с желчнокаменной болезнью. Фундаментальные исследования. 2013; 7: 51–4.
[Gaus O.V., Akhmedov V.A. Immunologicheskie paralleli v techenii metabolicheskogo sindroma, assotsiirovannogo s zhelchnokamennoi bolezn'iu . Fundamental'nye issledovaniia. 2013; 7: 51–4 (in Russian).]
11. Гаус О.В., Ахмедов В.А. Клинико-биохимические и иммунологические особенности желчнокаменной болезни, ассоциированной с метаболическим синдромом. Вестн. НГУ. Серия: Биология, клиническая медицина. 2013; 10 (3): 125–9.
[Gaus O.V., Akhmedov V.A. Kliniko-biokhimicheskie i immunologicheskie osobennosti zhelchnokamennoi bolezni, assotsiirovannoi s metabolicheskim sindromom. Vestn. NGU. Seriia: Biologiia, klinicheskaia meditsina. 2013; 10 (3): 125–9 (in Russian).]
12. Ливзан М.А., Кролевец Т.С., Лаптева И.В. Неалкогольная жировая болезнь печени у лиц с абдоминальным типом ожирения. Доказательная гастроэнтерология. 2014; 3 (4): 8–14.
[Livzan M.A., Krolevets T.S., Lapteva I.V. Nealkogol'naia zhirovaia bolezn' pecheni u lits s abdominal'nym tipom ozhireniia. Dokazatel'naia gastroenterologiia. 2014; 3 (4): 8–14 (in Russian).]
13. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med 2017; 14 (1): 45.
14. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver – the link between adipocytes and hepatocytes. Digestion 2011; 83 (1–2): 124–33.
15. Dongiovanni P, Valenti L, Rametta R et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 267–73.
16. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461–5.
17. Ливзан М.А., Лаптева И.В., Миллер Т.С. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением и избыточной массой тела. Эксперим. и клин. гастроэнтерология. 2014; 8 (108): 27–33.
[Livzan M.A., Lapteva I.V., Miller T.S. Rol' leptina i leptinorezistentnosti v formirovanii nealkogol'noi zhirovoi bolezni pecheni u lits s ozhireniem i izbytochnoi massoi tela. Eksperim. i klin. gastroenterologiia. 2014; 8 (108): 27–33 (in Russian).]
18. Кролевец Т.С., Ливзан М.А., Лаптева И.В., Черкащенко Н.А. Лептинорезистентность у пациентов с неалкогольной жировой болезнью печени, ассоциированной с ожирением и избыточной массой тела. Мед. совет. 2015; 13: 58–62.
[Krolevets T.S., Livzan M.A., Lapteva I.V., Cherkashchenko N.A. Leptinorezistentnost' u patsientov s nealkogol'noi zhirovoi bolezn'iu pecheni, assotsiirovannoi s ozhireniem i izbytochnoi massoi tela. Med. sovet. 2015; 13: 58–62 (in Russian).]
19. Crujeiras AB, Carreira MC, Cabia B et al. Leptin resistance in obesity: An epigenetic landscape. Life Sci 2015; 140: 57–63.
20. Javor ED, Ghany MG, Cochran EK et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005; 41: 753–60.
21. Angulo P, Alba LM, Petrovic LM et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatology 2014; 41: 943–9.
22. Michelino DR, Malaguarnera, L. Genetic variants in candidate genes influencing NAFLD progression. J Mol Med 2012; 90: 105–18.
23. Ahmed MH, Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first? Scand J Gastroenterol 2014; 49 (5): 521–7.
24. Di Ciaula A, Wang DQ, Portincasa P. Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention. Exp Rev Gastroenterol Hepatol 2019; 13 (2): 157–71.
25. Ахмедов В.А., Гаус О.В. Поражение органов гепатобилиарной системы и поджелудочной железы при ожирении. Терапевтический архив. 2017; 89 (1): 128–33.
[Akhmedov V.A., Gaus O.V. Porazhenie organov gepatobiliarnoi sistemy i podzheludochnoi zhelezy pri ozhirenii. Therapeutic Archive. 2017; 89 (1): 128–33 (in Russian).]
26. Кононов А.В., Ливзан М.А. Медицина, основанная на доказательствах, в практике клинического патолога. Сибирский Консилиум. 2002; 2: 18–22.
[Kononov A.V., Livzan M.A. Meditsina, osnovannaia na dokazatel'stvakh, v praktike klinicheskogo patologa. Sibirskii Konsilium. 2002; 2: 18–22 (in Russian).]
27. Cong P, Pricolo V, Biancani P, Behar J. Effects of cholesterol on CCK-1 receptors and caveolin-3 proteins recycling in human gallbladder muscle. Am J Physiol Gastrointest Liver Physiol 2010; 299 (3): G742–G750.
28. Махов В.М., Ромасенко Л.В., Турко Т.В. Коморбидность дисфункциональных расстройств органов пищеварения. Рус. мед. журн. Болезни органов пищеварения. 2007; 9 (2): 37–42.
[Makhov V.M., Romasenko L.V., Turko T.V. Komorbidnost' disfunktsional'nykh rasstroistv organov pishchevareniia. Rus. med. zhurn. Bolezni organov pishchevareniia. 2007; 9 (2): 37–42 (in Russian).]
29. Prasenjit Manna, Sushil K Jain. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metabolic Syndrome and Related Disorders 2015; 13 (10): 423–44.
30. Yu SJ, Kim W, Kim D et al. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine (Baltimore) 2015; 94 (48): e2159.
31. Boursier J, Mueller O, Barret M et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016; 63 (3): 764–75.
32. Yuan L, Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol 2015; 7 (28): 2811–88.
33. Fuchs CD, Traussnigg SA., Trauner M. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2016; 36 (1): 69–86.
34. Zhang DY, Zhu L, Liu HN et al. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. Drug Des Devel Ther 2019; 13: 2249–70.
35. Brar PC, Kohn B. Use of the microbiome in the management of children with type 2 diabetes mellitus. Curr Opin Pediatr 2019; 31 (4): 524–30.
36. Aron-Wisnewsky J, Clément K, Nieuwdorp M. Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes? Curr Diab Rep 2019; 19 (8): 51.
37. Patil MB, Ragav ED. A Clinical, Biochemical Profile of Type-2 Diabetes in Women with Special Reference to Vitamine-D Status in Obese and Non-Obese. J Assoc Physicians India 2018; 66 (12): 21–4.
38. Greco EA, Lenzi A, Migliaccio S. Role of Hypovitaminosis D in the Pathogenesis of Obe-sity-Induced Insulin Resistance. Nutrients 2019;11 (7): pii: E1506.
39. Piccolo BD, Hall LM, Stephensen CB et al. Circulating 25-Hydroxyvitamin D Concentrations in Overweight and Obese Adults Are Explained by Sun Exposure, Skin Reflectance, and Body Composition. Curr Dev Nutr 2019; 3 (7): nzz065.
40. Rafiq S, Jeppesen PB. Body Mass Index, Vitamin D, and Type 2 Diabetes: A Systematic Review and Meta-Analysis. Nutrients 2018; 10 (9): E1182.
41. Acalovschi M. Gallstones in patients with liver cirrhosis: Incidence, etiology, clinical and therapeutical aspects. World J Gastroenterol 2014; 20 (23): 7277–85.
42. Ruhl CE, Everhart JE. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol 2013; 108: 952–8.
43. Kwak MS, Kim D, Chung GE et al. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol 2015; 21: 6287–95.
44. Nervi F, Arrese M. Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? Am J Gastroenterol 2013; 108 (6): 959–61.
45. Shen C, Wu X, Xu C et al. Association of cholecystectomy with metabolic syndrome in a Chinese population. PLoS One 2014; 9 (2): e88189.
46. ChenY, Yu Tian SW. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiology to biochemical mechanisms. Lab Invest 2018; 98: 7–14.
47. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138–53.
48. Targher G, Byrne CD, Lonardo A et al. Non‐alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta‐analysis. J Hepatol 2016; 65: 589–600.
49. Драпкина О.М., Яфарова А.А. Неалкогольная жировая болезнь печени и сердечно-сосудистый риск: состояние проблемы. Рацион. фармакотерапия в кардиологии. 2017; 13 (5): 645–50.
[Drapkina O.M., Iafarova A.A. Nealkogol'naia zhirovaia bolezn' pecheni i serdechno-sosudistyi risk: sostoianie problemy. Ratsion. farmakoterapiia v kardiologii. 2017; 13 (5): 645–50 (in Russian).]
50. Fairfield CJ, Wigmore SJ, Harrison EM. Gallstone Disease and the Risk of Cardiovascular Disease. Sci Rep 2019; 9 (1): 5830.
2. Jaruvongvanich V, Sanguankeo A, Upala S. Signtificant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A systematic Review and Meta-Analisys. Dig Dis Sci 2016; 61 (8): 2389–96.
3. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol 2013; 19 (45): 8301–11.
4. McQuillian GM, McLean JE, Chiappa M et al. National Health and Nutrition Examination Survey Biospecimen Program: NHANES III (1988-1994) and NHANES 1999-2014. Vital Health Stat 2. 2015; 170: 1–14.
5. Fracanzani AL, Valenti L, Russello M et al. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non- Alcoholic Fatty Liver Disease. PLoS ONE 2012; 7 (7): e41183.
6. Komova A.G., Maevskaia M.V., Ivashkin V.T. Printsipy effektivnoi diagnostiki diffuznykh zabolevanii pecheni na ambulatornom etape. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2014; 24 (5): 36–41 (in Russian).
7. Ivashkin V.T., Maevskaia M.V., Pavlov Ch.S. et al. Klinicheskie rekomendatsii po diagnostike i lecheniiu nealkogol'noi zhirovoi bolezni pecheni Rossiiskogo obshchestva po izucheniiu pecheni i Rossiiskoi gastroenterologicheskoi assotsiatsii. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2016; 26 (2): 24–42 (in Russian).
8. EASL. Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016; 65 (1): 146–81.
9. Livzan M.A. et al. Gormony zhirovoi tkani i nealkogol'naia zhirovaia bolezn' pecheni pri metabolicheskom sindrome. Dnevnik kazanskoi meditsinskoi shkoly. 2014; 1 (4): 44–8 (in Russian).
10. Gaus O.V., Akhmedov V.A. Immunologicheskie paralleli v techenii metabolicheskogo sindroma, assotsiirovannogo s zhelchnokamennoi bolezn'iu . Fundamental'nye issledovaniia. 2013; 7: 51–4 (in Russian).
11.Gaus O.V., Akhmedov V.A. Kliniko-biokhimicheskie i immunologicheskie osobennosti zhelchnokamennoi bolezni, assotsiirovannoi s metabolicheskim sindromom. Vestn. NGU. Seriia: Biologiia, klinicheskaia meditsina. 2013; 10 (3): 125–9 (in Russian).
12. Livzan M.A., Krolevets T.S., Lapteva I.V. Nealkogol'naia zhirovaia bolezn' pecheni u lits s abdominal'nym tipom ozhireniia. Dokazatel'naia gastroenterologiia. 2014; 3 (4): 8–14 (in Russian).
13. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med 2017; 14 (1): 45.
14. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver – the link between adipocytes and hepatocytes. Digestion 2011; 83 (1–2): 124–33.
15. Dongiovanni P, Valenti L, Rametta R et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 267–73.
16. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461–5.
17. Livzan M.A., Lapteva I.V., Miller T.S. Rol' leptina i leptinorezistentnosti v formirovanii nealkogol'noi zhirovoi bolezni pecheni u lits s ozhireniem i izbytochnoi massoi tela. Eksperim. i klin. gastroenterologiia. 2014; 8 (108): 27–33 (in Russian).
18. Krolevets T.S., Livzan M.A., Lapteva I.V., Cherkashchenko N.A. Leptinorezistentnost' u patsientov s nealkogol'noi zhirovoi bolezn'iu pecheni, assotsiirovannoi s ozhireniem i izbytochnoi massoi tela. Med. sovet. 2015; 13: 58–62 (in Russian).
19. Crujeiras AB, Carreira MC, Cabia B et al. Leptin resistance in obesity: An epigenetic landscape. Life Sci 2015; 140: 57–63.
20. Javor ED, Ghany MG, Cochran EK et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005; 41: 753–60.
21. Angulo P, Alba LM, Petrovic LM et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatology 2014; 41: 943–9.
22. Michelino DR, Malaguarnera, L. Genetic variants in candidate genes influencing NAFLD progression. J Mol Med 2012; 90: 105–18.
23. Ahmed MH, Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first? Scand J Gastroenterol 2014; 49 (5): 521–7.
24. Di Ciaula A, Wang DQ, Portincasa P. Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention. Exp Rev Gastroenterol Hepatol 2019; 13 (2): 157–71.
25. Akhmedov V.A., Gaus O.V. Porazhenie organov gepatobiliarnoi sistemy i podzheludochnoi zhelezy pri ozhirenii. Therapeutic Archive. 2017; 89 (1): 128–33 (in Russian).
26. Kononov A.V., Livzan M.A. Meditsina, osnovannaia na dokazatel'stvakh, v praktike klinicheskogo patologa. Sibirskii Konsilium. 2002; 2: 18–22 (in Russian).
27. Cong P, Pricolo V, Biancani P, Behar J. Effects of cholesterol on CCK-1 receptors and caveolin-3 proteins recycling in human gallbladder muscle. Am J Physiol Gastrointest Liver Physiol 2010; 299 (3): G742–G750.
28. Makhov V.M., Romasenko L.V., Turko T.V. Komorbidnost' disfunktsional'nykh rasstroistv organov pishchevareniia. Rus. med. zhurn. Bolezni organov pishchevareniia. 2007; 9 (2): 37–42 (in Russian).
29. Prasenjit Manna, Sushil K Jain. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metabolic Syndrome and Related Disorders 2015; 13 (10): 423–44.
30. Yu SJ, Kim W, Kim D et al. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine (Baltimore) 2015; 94 (48): e2159.
31. Boursier J, Mueller O, Barret M et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016; 63 (3): 764–75.
32. Yuan L, Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol 2015; 7 (28): 2811–88.
33. Fuchs CD, Traussnigg SA., Trauner M. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2016; 36 (1): 69–86.
34. Zhang DY, Zhu L, Liu HN et al. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. Drug Des Devel Ther 2019; 13: 2249–70.
35. Brar PC, Kohn B. Use of the microbiome in the management of children with type 2 diabetes mellitus. Curr Opin Pediatr 2019; 31 (4): 524–30.
36. Aron-Wisnewsky J, Clément K, Nieuwdorp M. Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes? Curr Diab Rep 2019; 19 (8): 51.
37. Patil MB, Ragav ED. A Clinical, Biochemical Profile of Type-2 Diabetes in Women with Special Reference to Vitamine-D Status in Obese and Non-Obese. J Assoc Physicians India 2018; 66 (12): 21–4.
38. Greco EA, Lenzi A, Migliaccio S. Role of Hypovitaminosis D in the Pathogenesis of Obe-sity-Induced Insulin Resistance. Nutrients 2019;11 (7): pii: E1506.
39. Piccolo BD, Hall LM, Stephensen CB et al. Circulating 25-Hydroxyvitamin D Concentrations in Overweight and Obese Adults Are Explained by Sun Exposure, Skin Reflectance, and Body Composition. Curr Dev Nutr 2019; 3 (7): nzz065.
40. Rafiq S, Jeppesen PB. Body Mass Index, Vitamin D, and Type 2 Diabetes: A Systematic Review and Meta-Analysis. Nutrients 2018; 10 (9): E1182.
41. Acalovschi M. Gallstones in patients with liver cirrhosis: Incidence, etiology, clinical and therapeutical aspects. World J Gastroenterol 2014; 20 (23): 7277–85.
42. Ruhl CE, Everhart JE. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol 2013; 108: 952–8.
43. Kwak MS, Kim D, Chung GE et al. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol 2015; 21: 6287–95.
44. Nervi F, Arrese M. Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? Am J Gastroenterol 2013; 108 (6): 959–61.
45. Shen C, Wu X, Xu C et al. Association of cholecystectomy with metabolic syndrome in a Chinese population. PLoS One 2014; 9 (2): e88189.
46. ChenY, Yu Tian SW. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiology to biochemical mechanisms. Lab Invest 2018; 98: 7–14.
47. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138–53.
48. Targher G, Byrne CD, Lonardo A et al. Non‐alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta‐analysis. J Hepatol 2016; 65: 589–600.
49. Drapkina O.M., Iafarova A.A. Nealkogol'naia zhirovaia bolezn' pecheni i serdechno-sosudistyi risk: sostoianie problemy. Ratsion. farmakoterapiia v kardiologii. 2017; 13 (5): 645–50 (in Russian).
50. Fairfield CJ, Wigmore SJ, Harrison EM. Gallstone Disease and the Risk of Cardiovascular Disease. Sci Rep 2019; 9 (1): 5830.
[Ivashkin V.T., Drapkina O.M., Maev I.V. et al. Rasprostranennost' nealkogol'noi zhirovoi bolezni pecheni u patsientov ambulatorno-poliklinicheskoi praktiki v Rossiiskoi Federatsii: rezul'taty issledovaniia DIREG 2. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2015; 25 (6): 31–41 (in Russian).]
2. Jaruvongvanich V, Sanguankeo A, Upala S. Signtificant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A systematic Review and Meta-Analisys. Dig Dis Sci 2016; 61 (8): 2389–96.
3. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol 2013; 19 (45): 8301–11.
4. McQuillian GM, McLean JE, Chiappa M et al. National Health and Nutrition Examination Survey Biospecimen Program: NHANES III (1988-1994) and NHANES 1999-2014. Vital Health Stat 2. 2015; 170: 1–14.
5. Fracanzani AL, Valenti L, Russello M et al. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non- Alcoholic Fatty Liver Disease. PLoS ONE 2012; 7 (7): e41183.
6. Комова А.Г., Маевская М.В., Ивашкин В.Т. Принципы эффективной диагностики диффузных заболеваний печени на амбулаторном этапе. Рос. журн. гастроэнтерологии, гепатологии и колопроктологии. 2014; 24 (5): 36–41.
[Komova A.G., Maevskaia M.V., Ivashkin V.T. Printsipy effektivnoi diagnostiki diffuznykh zabolevanii pecheni na ambulatornom etape. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2014; 24 (5): 36–41 (in Russian).]
7. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Рос. журн. гастроэнтерологии, гепатологии и колопроктологии. 2016; 26 (2): 24–42.
[Ivashkin V.T., Maevskaia M.V., Pavlov Ch.S. et al. Klinicheskie rekomendatsii po diagnostike i lecheniiu nealkogol'noi zhirovoi bolezni pecheni Rossiiskogo obshchestva po izucheniiu pecheni i Rossiiskoi gastroenterologicheskoi assotsiatsii. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2016; 26 (2): 24–42 (in Russian).]
8. EASL. Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016; 65 (1): 146–81.
9. Ливзан М.А. и др. Гормоны жировой ткани и неалкогольная жировая болезнь печени при метаболическом синдроме. Дневник казанской медицинской школы. 2014; 1 (4): 44–8.
[Livzan M.A. et al. Gormony zhirovoi tkani i nealkogol'naia zhirovaia bolezn' pecheni pri metabolicheskom sindrome. Dnevnik kazanskoi meditsinskoi shkoly. 2014; 1 (4): 44–8 (in Russian).]
10. Гаус О.В., Ахмедов В.А. Иммунологические параллели в течении метаболического синдрома, ассоциированного с желчнокаменной болезнью. Фундаментальные исследования. 2013; 7: 51–4.
[Gaus O.V., Akhmedov V.A. Immunologicheskie paralleli v techenii metabolicheskogo sindroma, assotsiirovannogo s zhelchnokamennoi bolezn'iu . Fundamental'nye issledovaniia. 2013; 7: 51–4 (in Russian).]
11. Гаус О.В., Ахмедов В.А. Клинико-биохимические и иммунологические особенности желчнокаменной болезни, ассоциированной с метаболическим синдромом. Вестн. НГУ. Серия: Биология, клиническая медицина. 2013; 10 (3): 125–9.
[Gaus O.V., Akhmedov V.A. Kliniko-biokhimicheskie i immunologicheskie osobennosti zhelchnokamennoi bolezni, assotsiirovannoi s metabolicheskim sindromom. Vestn. NGU. Seriia: Biologiia, klinicheskaia meditsina. 2013; 10 (3): 125–9 (in Russian).]
12. Ливзан М.А., Кролевец Т.С., Лаптева И.В. Неалкогольная жировая болезнь печени у лиц с абдоминальным типом ожирения. Доказательная гастроэнтерология. 2014; 3 (4): 8–14.
[Livzan M.A., Krolevets T.S., Lapteva I.V. Nealkogol'naia zhirovaia bolezn' pecheni u lits s abdominal'nym tipom ozhireniia. Dokazatel'naia gastroenterologiia. 2014; 3 (4): 8–14 (in Russian).]
13. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med 2017; 14 (1): 45.
14. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver – the link between adipocytes and hepatocytes. Digestion 2011; 83 (1–2): 124–33.
15. Dongiovanni P, Valenti L, Rametta R et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 267–73.
16. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461–5.
17. Ливзан М.А., Лаптева И.В., Миллер Т.С. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением и избыточной массой тела. Эксперим. и клин. гастроэнтерология. 2014; 8 (108): 27–33.
[Livzan M.A., Lapteva I.V., Miller T.S. Rol' leptina i leptinorezistentnosti v formirovanii nealkogol'noi zhirovoi bolezni pecheni u lits s ozhireniem i izbytochnoi massoi tela. Eksperim. i klin. gastroenterologiia. 2014; 8 (108): 27–33 (in Russian).]
18. Кролевец Т.С., Ливзан М.А., Лаптева И.В., Черкащенко Н.А. Лептинорезистентность у пациентов с неалкогольной жировой болезнью печени, ассоциированной с ожирением и избыточной массой тела. Мед. совет. 2015; 13: 58–62.
[Krolevets T.S., Livzan M.A., Lapteva I.V., Cherkashchenko N.A. Leptinorezistentnost' u patsientov s nealkogol'noi zhirovoi bolezn'iu pecheni, assotsiirovannoi s ozhireniem i izbytochnoi massoi tela. Med. sovet. 2015; 13: 58–62 (in Russian).]
19. Crujeiras AB, Carreira MC, Cabia B et al. Leptin resistance in obesity: An epigenetic landscape. Life Sci 2015; 140: 57–63.
20. Javor ED, Ghany MG, Cochran EK et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005; 41: 753–60.
21. Angulo P, Alba LM, Petrovic LM et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatology 2014; 41: 943–9.
22. Michelino DR, Malaguarnera, L. Genetic variants in candidate genes influencing NAFLD progression. J Mol Med 2012; 90: 105–18.
23. Ahmed MH, Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first? Scand J Gastroenterol 2014; 49 (5): 521–7.
24. Di Ciaula A, Wang DQ, Portincasa P. Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention. Exp Rev Gastroenterol Hepatol 2019; 13 (2): 157–71.
25. Ахмедов В.А., Гаус О.В. Поражение органов гепатобилиарной системы и поджелудочной железы при ожирении. Терапевтический архив. 2017; 89 (1): 128–33.
[Akhmedov V.A., Gaus O.V. Porazhenie organov gepatobiliarnoi sistemy i podzheludochnoi zhelezy pri ozhirenii. Therapeutic Archive. 2017; 89 (1): 128–33 (in Russian).]
26. Кононов А.В., Ливзан М.А. Медицина, основанная на доказательствах, в практике клинического патолога. Сибирский Консилиум. 2002; 2: 18–22.
[Kononov A.V., Livzan M.A. Meditsina, osnovannaia na dokazatel'stvakh, v praktike klinicheskogo patologa. Sibirskii Konsilium. 2002; 2: 18–22 (in Russian).]
27. Cong P, Pricolo V, Biancani P, Behar J. Effects of cholesterol on CCK-1 receptors and caveolin-3 proteins recycling in human gallbladder muscle. Am J Physiol Gastrointest Liver Physiol 2010; 299 (3): G742–G750.
28. Махов В.М., Ромасенко Л.В., Турко Т.В. Коморбидность дисфункциональных расстройств органов пищеварения. Рус. мед. журн. Болезни органов пищеварения. 2007; 9 (2): 37–42.
[Makhov V.M., Romasenko L.V., Turko T.V. Komorbidnost' disfunktsional'nykh rasstroistv organov pishchevareniia. Rus. med. zhurn. Bolezni organov pishchevareniia. 2007; 9 (2): 37–42 (in Russian).]
29. Prasenjit Manna, Sushil K Jain. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metabolic Syndrome and Related Disorders 2015; 13 (10): 423–44.
30. Yu SJ, Kim W, Kim D et al. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine (Baltimore) 2015; 94 (48): e2159.
31. Boursier J, Mueller O, Barret M et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016; 63 (3): 764–75.
32. Yuan L, Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol 2015; 7 (28): 2811–88.
33. Fuchs CD, Traussnigg SA., Trauner M. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2016; 36 (1): 69–86.
34. Zhang DY, Zhu L, Liu HN et al. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. Drug Des Devel Ther 2019; 13: 2249–70.
35. Brar PC, Kohn B. Use of the microbiome in the management of children with type 2 diabetes mellitus. Curr Opin Pediatr 2019; 31 (4): 524–30.
36. Aron-Wisnewsky J, Clément K, Nieuwdorp M. Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes? Curr Diab Rep 2019; 19 (8): 51.
37. Patil MB, Ragav ED. A Clinical, Biochemical Profile of Type-2 Diabetes in Women with Special Reference to Vitamine-D Status in Obese and Non-Obese. J Assoc Physicians India 2018; 66 (12): 21–4.
38. Greco EA, Lenzi A, Migliaccio S. Role of Hypovitaminosis D in the Pathogenesis of Obe-sity-Induced Insulin Resistance. Nutrients 2019;11 (7): pii: E1506.
39. Piccolo BD, Hall LM, Stephensen CB et al. Circulating 25-Hydroxyvitamin D Concentrations in Overweight and Obese Adults Are Explained by Sun Exposure, Skin Reflectance, and Body Composition. Curr Dev Nutr 2019; 3 (7): nzz065.
40. Rafiq S, Jeppesen PB. Body Mass Index, Vitamin D, and Type 2 Diabetes: A Systematic Review and Meta-Analysis. Nutrients 2018; 10 (9): E1182.
41. Acalovschi M. Gallstones in patients with liver cirrhosis: Incidence, etiology, clinical and therapeutical aspects. World J Gastroenterol 2014; 20 (23): 7277–85.
42. Ruhl CE, Everhart JE. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol 2013; 108: 952–8.
43. Kwak MS, Kim D, Chung GE et al. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol 2015; 21: 6287–95.
44. Nervi F, Arrese M. Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? Am J Gastroenterol 2013; 108 (6): 959–61.
45. Shen C, Wu X, Xu C et al. Association of cholecystectomy with metabolic syndrome in a Chinese population. PLoS One 2014; 9 (2): e88189.
46. ChenY, Yu Tian SW. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiology to biochemical mechanisms. Lab Invest 2018; 98: 7–14.
47. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138–53.
48. Targher G, Byrne CD, Lonardo A et al. Non‐alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta‐analysis. J Hepatol 2016; 65: 589–600.
49. Драпкина О.М., Яфарова А.А. Неалкогольная жировая болезнь печени и сердечно-сосудистый риск: состояние проблемы. Рацион. фармакотерапия в кардиологии. 2017; 13 (5): 645–50.
[Drapkina O.M., Iafarova A.A. Nealkogol'naia zhirovaia bolezn' pecheni i serdechno-sosudistyi risk: sostoianie problemy. Ratsion. farmakoterapiia v kardiologii. 2017; 13 (5): 645–50 (in Russian).]
50. Fairfield CJ, Wigmore SJ, Harrison EM. Gallstone Disease and the Risk of Cardiovascular Disease. Sci Rep 2019; 9 (1): 5830.
________________________________________________
2. Jaruvongvanich V, Sanguankeo A, Upala S. Signtificant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A systematic Review and Meta-Analisys. Dig Dis Sci 2016; 61 (8): 2389–96.
3. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol 2013; 19 (45): 8301–11.
4. McQuillian GM, McLean JE, Chiappa M et al. National Health and Nutrition Examination Survey Biospecimen Program: NHANES III (1988-1994) and NHANES 1999-2014. Vital Health Stat 2. 2015; 170: 1–14.
5. Fracanzani AL, Valenti L, Russello M et al. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non- Alcoholic Fatty Liver Disease. PLoS ONE 2012; 7 (7): e41183.
6. Komova A.G., Maevskaia M.V., Ivashkin V.T. Printsipy effektivnoi diagnostiki diffuznykh zabolevanii pecheni na ambulatornom etape. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2014; 24 (5): 36–41 (in Russian).
7. Ivashkin V.T., Maevskaia M.V., Pavlov Ch.S. et al. Klinicheskie rekomendatsii po diagnostike i lecheniiu nealkogol'noi zhirovoi bolezni pecheni Rossiiskogo obshchestva po izucheniiu pecheni i Rossiiskoi gastroenterologicheskoi assotsiatsii. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2016; 26 (2): 24–42 (in Russian).
8. EASL. Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016; 65 (1): 146–81.
9. Livzan M.A. et al. Gormony zhirovoi tkani i nealkogol'naia zhirovaia bolezn' pecheni pri metabolicheskom sindrome. Dnevnik kazanskoi meditsinskoi shkoly. 2014; 1 (4): 44–8 (in Russian).
10. Gaus O.V., Akhmedov V.A. Immunologicheskie paralleli v techenii metabolicheskogo sindroma, assotsiirovannogo s zhelchnokamennoi bolezn'iu . Fundamental'nye issledovaniia. 2013; 7: 51–4 (in Russian).
11.Gaus O.V., Akhmedov V.A. Kliniko-biokhimicheskie i immunologicheskie osobennosti zhelchnokamennoi bolezni, assotsiirovannoi s metabolicheskim sindromom. Vestn. NGU. Seriia: Biologiia, klinicheskaia meditsina. 2013; 10 (3): 125–9 (in Russian).
12. Livzan M.A., Krolevets T.S., Lapteva I.V. Nealkogol'naia zhirovaia bolezn' pecheni u lits s abdominal'nym tipom ozhireniia. Dokazatel'naia gastroenterologiia. 2014; 3 (4): 8–14 (in Russian).
13. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med 2017; 14 (1): 45.
14. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver – the link between adipocytes and hepatocytes. Digestion 2011; 83 (1–2): 124–33.
15. Dongiovanni P, Valenti L, Rametta R et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 267–73.
16. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461–5.
17. Livzan M.A., Lapteva I.V., Miller T.S. Rol' leptina i leptinorezistentnosti v formirovanii nealkogol'noi zhirovoi bolezni pecheni u lits s ozhireniem i izbytochnoi massoi tela. Eksperim. i klin. gastroenterologiia. 2014; 8 (108): 27–33 (in Russian).
18. Krolevets T.S., Livzan M.A., Lapteva I.V., Cherkashchenko N.A. Leptinorezistentnost' u patsientov s nealkogol'noi zhirovoi bolezn'iu pecheni, assotsiirovannoi s ozhireniem i izbytochnoi massoi tela. Med. sovet. 2015; 13: 58–62 (in Russian).
19. Crujeiras AB, Carreira MC, Cabia B et al. Leptin resistance in obesity: An epigenetic landscape. Life Sci 2015; 140: 57–63.
20. Javor ED, Ghany MG, Cochran EK et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005; 41: 753–60.
21. Angulo P, Alba LM, Petrovic LM et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatology 2014; 41: 943–9.
22. Michelino DR, Malaguarnera, L. Genetic variants in candidate genes influencing NAFLD progression. J Mol Med 2012; 90: 105–18.
23. Ahmed MH, Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first? Scand J Gastroenterol 2014; 49 (5): 521–7.
24. Di Ciaula A, Wang DQ, Portincasa P. Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention. Exp Rev Gastroenterol Hepatol 2019; 13 (2): 157–71.
25. Akhmedov V.A., Gaus O.V. Porazhenie organov gepatobiliarnoi sistemy i podzheludochnoi zhelezy pri ozhirenii. Therapeutic Archive. 2017; 89 (1): 128–33 (in Russian).
26. Kononov A.V., Livzan M.A. Meditsina, osnovannaia na dokazatel'stvakh, v praktike klinicheskogo patologa. Sibirskii Konsilium. 2002; 2: 18–22 (in Russian).
27. Cong P, Pricolo V, Biancani P, Behar J. Effects of cholesterol on CCK-1 receptors and caveolin-3 proteins recycling in human gallbladder muscle. Am J Physiol Gastrointest Liver Physiol 2010; 299 (3): G742–G750.
28. Makhov V.M., Romasenko L.V., Turko T.V. Komorbidnost' disfunktsional'nykh rasstroistv organov pishchevareniia. Rus. med. zhurn. Bolezni organov pishchevareniia. 2007; 9 (2): 37–42 (in Russian).
29. Prasenjit Manna, Sushil K Jain. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metabolic Syndrome and Related Disorders 2015; 13 (10): 423–44.
30. Yu SJ, Kim W, Kim D et al. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine (Baltimore) 2015; 94 (48): e2159.
31. Boursier J, Mueller O, Barret M et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016; 63 (3): 764–75.
32. Yuan L, Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol 2015; 7 (28): 2811–88.
33. Fuchs CD, Traussnigg SA., Trauner M. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2016; 36 (1): 69–86.
34. Zhang DY, Zhu L, Liu HN et al. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. Drug Des Devel Ther 2019; 13: 2249–70.
35. Brar PC, Kohn B. Use of the microbiome in the management of children with type 2 diabetes mellitus. Curr Opin Pediatr 2019; 31 (4): 524–30.
36. Aron-Wisnewsky J, Clément K, Nieuwdorp M. Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes? Curr Diab Rep 2019; 19 (8): 51.
37. Patil MB, Ragav ED. A Clinical, Biochemical Profile of Type-2 Diabetes in Women with Special Reference to Vitamine-D Status in Obese and Non-Obese. J Assoc Physicians India 2018; 66 (12): 21–4.
38. Greco EA, Lenzi A, Migliaccio S. Role of Hypovitaminosis D in the Pathogenesis of Obe-sity-Induced Insulin Resistance. Nutrients 2019;11 (7): pii: E1506.
39. Piccolo BD, Hall LM, Stephensen CB et al. Circulating 25-Hydroxyvitamin D Concentrations in Overweight and Obese Adults Are Explained by Sun Exposure, Skin Reflectance, and Body Composition. Curr Dev Nutr 2019; 3 (7): nzz065.
40. Rafiq S, Jeppesen PB. Body Mass Index, Vitamin D, and Type 2 Diabetes: A Systematic Review and Meta-Analysis. Nutrients 2018; 10 (9): E1182.
41. Acalovschi M. Gallstones in patients with liver cirrhosis: Incidence, etiology, clinical and therapeutical aspects. World J Gastroenterol 2014; 20 (23): 7277–85.
42. Ruhl CE, Everhart JE. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol 2013; 108: 952–8.
43. Kwak MS, Kim D, Chung GE et al. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol 2015; 21: 6287–95.
44. Nervi F, Arrese M. Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? Am J Gastroenterol 2013; 108 (6): 959–61.
45. Shen C, Wu X, Xu C et al. Association of cholecystectomy with metabolic syndrome in a Chinese population. PLoS One 2014; 9 (2): e88189.
46. ChenY, Yu Tian SW. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiology to biochemical mechanisms. Lab Invest 2018; 98: 7–14.
47. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138–53.
48. Targher G, Byrne CD, Lonardo A et al. Non‐alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta‐analysis. J Hepatol 2016; 65: 589–600.
49. Drapkina O.M., Iafarova A.A. Nealkogol'naia zhirovaia bolezn' pecheni i serdechno-sosudistyi risk: sostoianie problemy. Ratsion. farmakoterapiia v kardiologii. 2017; 13 (5): 645–50 (in Russian).
50. Fairfield CJ, Wigmore SJ, Harrison EM. Gallstone Disease and the Risk of Cardiovascular Disease. Sci Rep 2019; 9 (1): 5830.
Авторы
Н.А. Черкащенко1, М.А. Ливзан*2, О.В. Гаус2, Т.С. Кролевец2
1. ФГБУЗ «Западно-Сибирский центр ФМБА России», Омск, Россия;
2. ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*mlivzan@yandex.ru
1. West Siberian Center of the Federal Medical and Biological Agency of Russia, Omsk, Russia;
2. Omsk State Medical University, Omsk, Russia
*mlivzan@yandex.ru
1. ФГБУЗ «Западно-Сибирский центр ФМБА России», Омск, Россия;
2. ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*mlivzan@yandex.ru
________________________________________________
1. West Siberian Center of the Federal Medical and Biological Agency of Russia, Omsk, Russia;
2. Omsk State Medical University, Omsk, Russia
*mlivzan@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.